Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10(2):149–57.

Article  PubMed  Google Scholar 

Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26: 100278.

Article  PubMed  Google Scholar 

Kuchuk I, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101–7.

Article  CAS  PubMed  Google Scholar 

Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219–27.

Article  PubMed  Google Scholar 

Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13–36.

Article  PubMed  Google Scholar 

Woopen H, Richter R, Chekerov R, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer. 2020;28(1):73–8.

Article  PubMed  Google Scholar 

Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021;26(1):1–17.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis (Version 2.2022). 2022. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 26 Apr 2022.

Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–88.

Article  PubMed  Google Scholar 

Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97.

Article  CAS  PubMed  Google Scholar 

Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Suppl 5):v119–33.

Article  CAS  PubMed  Google Scholar 

GlobeNewswire. Taiho Pharmaceutical obtains approval to manufacture and market NK1 receptor antagonist Arokaris® I.V. infusion 235mg in Japan 2022.

Helsinn Therapeutics US Inc. AKYNZEO® (netupitant and palonosetron) capsules, for oral use, and AKYNZEO® (fosnetupitant and palonosetron) for injection, for intravenous use: prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210493Orig1s003lbl.pdf. Accessed 26 Apr 2022.

Helsinn Birex Pharmaceuticals Ltd. Akynzeo 300 mg/0.5 mg hard capsules and Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion: summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_en.pdf. Accessed 26 Apr 2022.

Hata A, Okamoto I, Inui N, et al. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180–8.

Article  CAS  PubMed  Google Scholar 

Matsuura K, Tsurutani J, Inoue K, et al. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022;128(8):1692–8.

Article  CAS  PubMed  Google Scholar 

Shimada K, Taguchi S. Management of nausea, vomiting and anorexia due to anticancer agents [in Japanese]. Gan To Kagaku Ryoho. 2003;30(6):760–4.

PubMed  Google Scholar 

Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018;26(Suppl 1):5–9.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Recio S, Gascón P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int. 2015;2015: 495704.

Article  PubMed  PubMed Central  Google Scholar 

Shirley M. Netupitant/palonosetron: a review in chemotherapy-induced nausea and vomiting. Drugs. 2021;81(11):1331–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Celio L, Fabbroni C. Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2018;19(11):1267–77.

Article  CAS  PubMed  Google Scholar 

Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pharm Sci. 1999;88(9):922–7.

Article  CAS  PubMed  Google Scholar 

Sugawara S, Inui N, Kanehara M, et al. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer. 2019;125(22):4076–83.

Article  CAS  PubMed  Google Scholar 

Gilmore J, Bernareggi A. Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019;59(4):472–87.

Article  CAS  PubMed  Google Scholar 

Kurteva G, Chilingirova N, Rizzi G, Caccia T, Stella V, Bernareggi A. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Eur J Pharm Sci. 2019;139: 105041.

Article  CAS  PubMed  Google Scholar 

Spinelli T, Calcagnile S, Giuliano C, et al. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol. 2014;54(1):97–108.

Article  CAS  PubMed  Google Scholar 

Giuliano C, Lovati E, Funk C, Potthast M, Pietra C. In vitro drug-drug interaction studies with the antiemetic drug netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes [ESMO abstract 1618]. Ann Oncol. 2012;23(Suppl 9):ix520.

Article  Google Scholar 

Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013;21(10):2783–91.

Article  PubMed  Google Scholar 

Natale JJ, Spinelli T, Calcagnile S, et al. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: review of clinical data. J Oncol Pharm Pract. 2016;22(3):485–95.

Article  CAS  PubMed  Google Scholar 

Kitamura R, Araki H, Ikeda K. Estimation of brain NK1 receptor occupancy after fosnetupitant administration and its contribution to antiemetic efficacy in Japanese patients [abstract 2-C-P-079]. Presented at The 43rd Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, Yokohama, Japan; November 30–December 3, 2022. https://doi.org/10.50993/jsptsuppl.43.0_2-CP-079.

Hata A, Shiraishi Y, Inui N, et al. Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE). Oncol Ther. 2022;10(1):253–62.

Article  PubMed  PubMed Central  Google Scholar 

Fujii T, Nishimura N, Urayama KY, et al. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens. Anticancer Res. 2015;35(1):379–83.

CAS  PubMed  Google Scholar 

Leal AD, Kadakia KC, Looker S, et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014;22(5):1313–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lundberg JD, Crawford BS, Phillips G, Berger MJ, Wesolowski R. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 2014;22(6):1461–6.

Article  PubMed  PubMed Central  Google Scholar 

Matsumoto K, Takahashi M, Sato K, et al. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med. 2020;9(10):3319–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato Y, Kondo M, Inagaki A, et al. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer. 2014;5(5):390–7.

Article  PubMed  PubMed Central  Google Scholar 

Tsuda T, Kyomori C, Mizukami T, et al. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison. Mol Clin Oncol. 2016;4(4):603–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartzberg L, Navari R, Clark-Snow R, et al. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020;25(3):e589–97.

Article  CAS  PubMed  Google Scholar 

Schwartzberg L, Roeland E, Andric Z, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29(7):1535–40.

Article  CAS  PubMed  Google Scholar 

Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20(5):855–65.

Article  PubMed